Last updated on June 2019

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR ALK ROS1 or BRAF TKI Therapy

Brief description of study

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.

Clinical Study Identifier: NCT03042221

Find a site near you

Start Over